B. Lisboa

1.7k total citations
23 papers, 788 citations indexed

About

B. Lisboa is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, B. Lisboa has authored 23 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in B. Lisboa's work include Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (7 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). B. Lisboa is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (7 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). B. Lisboa collaborates with scholars based in Germany, Netherlands and United States. B. Lisboa's co-authors include Thomas Löning, Karin Milde‐Langosch, Christoph Thomssen, Lutz Riethdorf, Michael Untch, Jan-Ακε Gustafsson, W. Jonat, Matthias Geberth, M. Namer and M K Palmer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Cancer.

In The Last Decade

B. Lisboa

21 papers receiving 762 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Lisboa Germany	12	474	376	207	203	100	23	788
J.G.M. Klijn Netherlands	8	539 1.1×	251 0.7×	237 1.1×	249 1.2×	170 1.7×	19	840
RD Rubens United Kingdom	8	436 0.9×	421 1.1×	128 0.6×	162 0.8×	65 0.7×	9	691
Sylvie Romain France	16	555 1.2×	411 1.1×	158 0.8×	207 1.0×	76 0.8×	31	857
B Gairard France	13	337 0.7×	160 0.4×	213 1.0×	239 1.2×	42 0.4×	32	644
JFR Robertson United Kingdom	12	435 0.9×	333 0.9×	138 0.7×	327 1.6×	146 1.5×	13	830
John Cairns United Kingdom	7	835 1.8×	268 0.7×	188 0.9×	455 2.2×	90 0.9×	13	1.1k
Andrew Berchuck United States	10	375 0.8×	203 0.5×	149 0.7×	560 2.8×	52 0.5×	11	1.1k
R.S. Rampaul United Kingdom	14	431 0.9×	358 1.0×	132 0.6×	236 1.2×	95 0.9×	33	905
S. Johnston United Kingdom	18	508 1.1×	262 0.7×	371 1.8×	265 1.3×	212 2.1×	50	923
Philippe Haas Switzerland	8	578 1.2×	207 0.6×	100 0.5×	588 2.9×	230 2.3×	8	1.1k

Countries citing papers authored by B. Lisboa

Since Specialization

Citations

This map shows the geographic impact of B. Lisboa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Lisboa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Lisboa more than expected).

Fields of papers citing papers by B. Lisboa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Lisboa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Lisboa. The network helps show where B. Lisboa may publish in the future.

Co-authorship network of co-authors of B. Lisboa

This figure shows the co-authorship network connecting the top 25 collaborators of B. Lisboa. A scholar is included among the top collaborators of B. Lisboa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Lisboa. B. Lisboa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harbeck, Nadia, Manfred Schmitt, Christoph Meisner, et al.. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer. 49(8). 1825–1835. 127 indexed citations

Lorenzen, J., et al.. (2012). Second Opinion Assessment in Diagnostic Mammography at a Breast Cancer Centre. Geburtshilfe und Frauenheilkunde. 72(8). 734–739. 4 indexed citations

Nitz, Ulrike, Jens Huober, B. Lisboa, et al.. (2009). Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc.. Cancer Research. 69(2_Supplement). 78–78. 8 indexed citations

Harbeck, Nadia, Christoph Meisner, Peter M. Ravdin, et al.. (2009). Outcome Prediction in Node-Negative Breast Cancer Based on ASCO-Recommended Biomarkers uPA/PAI-1 Using the Final 10-Year Analysis of the Randomized Multicenter Chemo N0 Trial Compared to Adjuvant Online™.. Cancer Research. 69(24_Supplement). 4038–4038.

Ihnen, Maike, Volkmar Müller, Ralph M. Wirtz, et al.. (2008). Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Research and Treatment. 112(3). 419–427. 57 indexed citations

Huober, Jens, B. Lisboa, Nadia Harbeck, et al.. (2008). Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes. Journal of Clinical Oncology. 26(15_suppl). 515–515. 3 indexed citations

Meisner, Christoph, Caroline C. Friedel, Manfred Schmidt, et al.. (2006). Comparison of outcome prediction in node-negative breast cancer based on biomarkers uPA/PAI-1 or Adjuvant Online using the 10-year follow-up of the randomized multicenter Chemo N0 trial. Journal of Clinical Oncology. 24(18_suppl). 534–534. 5 indexed citations

Lorenzen, J., et al.. (2005). Diagnostische Mammographie und Sonographie: Korrelation von diagnostischer BI-RADS-Einstufung mit dem histologischen und klinischen Endbefund. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 177(11). 1545–1551. 7 indexed citations

Lorenzen, J., et al.. (2003). MR-Mammographie bei 0,5 Tesla: Menstruationszyklusabhängigkeit der Kontrastmittelanreicherung unter hormoneller Kontrazeption?. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 175(4). 502–506. 5 indexed citations

10.

Lorenzen, J., et al.. (2002). Perkutane Hochgeschwindigkeitsstanzbiopsie palpabler Brusttumoren: Ist die Sonographie notwendig?. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 174(9). 1142–1146. 3 indexed citations

11.

Jonat, W., M. Kaufmann, Willi Sauerbrei, et al.. (2002). Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study. Journal of Clinical Oncology. 20(24). 4628–4635. 246 indexed citations

12.

Bamberger, Ana‐Maria, et al.. (1999). Expression pattern of the AP-1 family in breast cancer: Association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. International Journal of Cancer. 84(5). 533–538. 84 indexed citations

13.

Thomssen, Christoph, et al.. (1998). Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.. PubMed. 12(1 Suppl 1). 36–9. 13 indexed citations

14.

Lisboa, B., et al.. (1997). Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 431(6). 375–381. 23 indexed citations

15.

Bschorer, Reinhard, Felix Blake, & B. Lisboa. (1997). Free flap transfer and the prevention of endothelial damage. Oral and Maxillofacial Surgery. 1(1-6). 235–238. 2 indexed citations

16.

Riethdorf, Lutz, et al.. (1997). Differential Expression of CD66a (BGP), a Cell Adhesion Molecule of the Carcinoembryonic Antigen Family, in Benign, Premalignant, and Malignant Lesions of the Human Mammary Gland. Journal of Histochemistry & Cytochemistry. 45(7). 957–963. 91 indexed citations

17.

Thomssen, Christoph, et al.. (1997). Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.. PubMed. 24(5 Suppl 17). S17–35. 23 indexed citations

18.

Lück, Hans‐Joachim, Christoph Thomssen, Andreas duBois, et al.. (1996). Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.. PubMed. 23(1 Suppl 1). 33–6. 21 indexed citations

19.

Gustafsson, Jan-Ακε & B. Lisboa. (1968). Biosynthesis of 6β-hydroxytestosterone from testosterone by human fetal liver microsomes. Steroids. 11(4). 555–563. 31 indexed citations

20.

Freerksen, E, R. Bönicke, & B. Lisboa. (1958). [The reaction of cycloserine in vivo].. PubMed. 12(1). 39–49. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact